Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)

This study has been terminated.
(See termination reason in detailed description)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00523042
First received: August 29, 2007
Last updated: February 28, 2017
Last verified: February 2017

August 29, 2007
February 28, 2017
August 30, 2007
February 28, 2008   (Final data collection date for primary outcome measure)
Changes in lung function, chest X-rays, or asthma exacerbation frequency [ Time Frame: after 52 weeks of treatment ]
Same as current
Complete list of historical versions of study NCT00523042 on ClinicalTrials.gov Archive Site
  • Diabetes control measured by change in HbA1c [ Time Frame: from baseline to end of treatment ]
  • Laboratory assessments (biochemistry, insulin antibodies, blood count) [ Time Frame: from baseline to end of treatment ]
  • Preprandial insulin doses [ Time Frame: for the duration of the trial ]
  • Diabetes control measured by change in HbA1c from baseline
  • Laboratory assessments (biochemistry, insulin antibodies, blood count)
  • Preprandial insulin doses
Not Provided
Not Provided
 
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
Inhaled Preprandial Human Insulin With the AERx® iMS Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Asthma: A 52-week, Open-label, Multinational, Randomised, Parallel Trial to Investigate Long-term Safety

This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).

This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Asthma
  • Drug: insulin aspart
    Treat-to-target dose titration scheme, injection s.c.
    Other Names:
    • NovoRapid®
    • NovoLog®
  • Drug: inhaled human insulin
    Treat-to-target dose titration scheme, inhalation.
  • Experimental: A
    Intervention: Drug: inhaled human insulin
  • Active Comparator: B
    Intervention: Drug: insulin aspart
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
10
February 28, 2008
February 28, 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 1 or type 2 diabetes
  • Treatment with insulin and/or oral anti-diabetic drugs
  • Asthma for at least 6 months
  • Positive airway reversibility/bronchoprovocation test or documented positive test in the last 3 years
  • HbA1C less than or equal to 11.0 %
  • Body Mass Index (BMI) less than or equal to 40.0 kg/m2

Exclusion Criteria:

  • Current smoking or smoking within the last 6 months
  • Other current acute or chronic pulmonary disease excluding asthma
  • Recurrent severe hypoglycaemia
  • Proliferative retinopathy or maculopathy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Former Serbia and Montenegro,   India,   Malaysia,   Slovakia
 
 
NCT00523042
NN1998-1616
No
Not Provided
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP